ClinicalTrials.gg
RecruitingNCT06696261Updated Jan 20, 2026

A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

A Phase 3 interventional study of Lianxiaxiaopi Granules and a simulated agent of Lianxiaxiaopi Granules in Postprandial Distress Syndrome, sponsored by Tasly Pharmaceutical Group Co., Ltd. Recruiting at 18 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are:

  1. Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo.
  2. Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome.
  3. Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.
02

Conditions studied

  • Postprandial Distress Syndrome
03

In context

Lead sponsor

Tasly Pharmaceutical Group Co., Ltd is the lead sponsor of 32 studies on the registry; 17 are open to participants now.

First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years old (including boundary value), gender is not limited;
  2. meet the diagnostic criteria for postprandial distress syndrome (Rome IV.);
  3. Meet the syndrome differentiation standards of Traditional Chinese Medicine for cold and heat miscellaneous syndromes;
  4. NRS score of at least one symptom of postprandial distress syndrome (postprandial fullness, discomfort, early satiety) in the screening period and baseline period≥ 4 points; and did not have moderate/severe epigastric pain syndrome (mid-epigastric burning sensation and mid-upper quadrant pain both \< 4 points);
  5. Those who did not have organic abnormal changes in the results of gastroscopy (including no abnormalities in gastroscopy, chronic non-atrophic gastritis/chronic superficial gastritis with erythema grade I and/or erosion that was flat and only grade I);
  6. Negative Helicobacter pylori test in 13C/14C breath test during the screening period;
  7. Voluntarily participate in clinical trials, sign , and understand and comply with research procedures.

Exclusion criteria

Exclusion Criteria:

  1. Those who have undergone Helicobacter pylori eradication treatment within 6 months before screening;
  2. Gastric mucosal erythema grade II or above, erosion is bulge or grade II or above, or accompanied by bleeding, bile reflux, ≥ 3 inflammatory polyps and other manifestations, or combined with pathological diagnosis of chronic atrophic gastritis, hyperplastic polyps, glandular polyps, etc.; or those who have been clearly diagnosed with dyspepsia caused by organic diseases of the digestive system, such as digestive tract tumors, hepatobiliary and pancreatic diseases, inflammatory bowel diseases, etc.; or those who have other diseases that affect the evaluation of dyspepsia-related symptoms in the past, such as reflux esophagitis, peptic ulcer, gastrointestinal bleeding, intestinal obstruction, etc.;
  3. Those who have been diagnosed with systemic diseases that seriously affect the function of the digestive tract, such as hyperthyroidism or hypothyroidism, diabetes, chronic renal insufficiency, connective tissue diseases, etc.;
  4. Patients with severe cardiovascular and cerebrovascular, liver, lung, kidney, blood or systemic diseases that affect their survival; or patients with severe mental illness in the past, such as moderate or severe depression/anxiety/bipolar disorder, etc.;
  5. Those who have a history of major abdominal surgery in the past, which may affect gastrointestinal function (except for appendectomy, cesarean section, endoscopic colon polyp resection and other surgeries that do not affect digestive function);
  6. Patients with abnormal liver function ( or AST >1.5 times the ) or abnormal renal function test (Cr> upper limit of normal);
  7. Glycosylated ≥ 6.5% or fasting blood glucose ≥7mmol/L during the screening period;
  8. Use of drugs or treatments that may have an impact on the effectiveness assessment of the trial drug within 2 weeks before screening (such as acid/antacids, gastrointestinal motility drugs, digestive enzymes, gastric mucosal protectors, antiemetics, antispasmodics, macrolide antimicrobials, azole antifungals, non-steroidal anti-inflammatory drugs, , anti-anxiety and depressants, analgesics, sedatives; as well as traditional Chinese medicine decoctions, proprietary Chinese medicines and acupuncture treatments for the treatment of functional dyspepsia, etc.);
  9. Pregnant and lactating women, who have a birth plan within one month after enrollment and the end of the trial;
  10. Those who suspect or have a history of alcohol or drug abuse;
  11. Participated in other clinical trials within 1 month before screening;
  12. Those who are suspected or known to be allergic to the ingredients of this medicine;
  13. According to the judgment of the investigator, it is not suitable to participate in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
342 participants (estimated)

Study arms

  • Experimental
    Lianxiaxiaopi Granules

    Drug: Lianxiaxiaopi Granules

  • Placebo comparator
    a simulated agent of Lianxiaxiaopi Granules

    Drug: a simulated agent of Lianxiaxiaopi Granules

Interventions

  • DrugLianxiaxiaopi Granules

    The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.

  • Druga simulated agent of Lianxiaxiaopi Granules

    The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Postprandial distress syndrome response rate

    Postprandial Distress Syndrome Response, the number of weeks in which the subject responded to the postprandial distress syndrome was greater than 50% of the weeks throughout the treatment period. Response week, if the two symptoms of postprandial fullness and discomfort and early satiety decreased by ≥50% compared with the baseline per week, the response week was calculated by the diary card score.

    Time frame: The end of Week 8

Secondary outcomes

  1. postprandial distress syndrome score change from baseline

    "The dyspepsia symptom scoring criteria" consists of 5 items, with a minimum score of 0 and a maximum of 10 points for each item. 0 points: asymptomatic; 1-3 points: mild disturbance, mild symptoms, almost no impact on daily life and work; 4-6 points: moderate disturbance, still tolerable, partially affecting daily life and work; 7-10 points: Severe disturbance, unbearable, unable to carry out daily life and work. The minimum score of the scale is 0 points, the maximum is 50 points, and the higher the score, the more serious the disease.

    Time frame: The end of Week 8

  2. single symptom response rate

    Time frame: The end of Week 8

  3. the change value of single symptom score from baseline

    "The dyspepsia symptom scoring criteria" consists of 5 items, with a minimum score of 0 and a maximum of 10 points for each item. 0 points: asymptomatic; 1-3 points: mild disturbance, mild symptoms, almost no impact on daily life and work; 4-6 points: moderate disturbance, still tolerable, partially affecting daily life and work; 7-10 points: Severe disturbance, unbearable, unable to carry out daily life and work.

    Time frame: The end of Week 8

  4. the change from baseline in epigstric pain syndrome score

    "The dyspepsia symptom scoring criteria" consists of 5 items, with a minimum score of 0 and a maximum of 10 points for each item. 0 points: asymptomatic; 1-3 points: mild disturbance, mild symptoms, almost no impact on daily life and work; 4-6 points: moderate disturbance, still tolerable, partially affecting daily life and work; 7-10 points: Severe disturbance, unbearable, unable to carry out daily life and work. The score for epigastric pain syndrome includes the sum of the scores for mid-upper quadrant pain and mid-upper quadrant burning sensation

    Time frame: The end of Week 8

  5. epigastric pain syndrome response rate

    Time frame: The end of Week 8

  6. the change from baseline in the total score of TCM

    The TCM Syndrome Scale for Postprandial Distress Syndrome contains two main symptoms, each of which can be evaluated as 0, 2, 4 and 6 points. 6 sub-symptoms, each of which can be evaluated as 0, 1, 2, and 3 points. The scale has a minimum score of 0 and a maximum of 30 points, with the higher the score, the more severe the condition.

    Time frame: The end of Week 8

  7. the change value of TCM single symptom score from baseline

    The TCM Syndrome Scale for Postprandial Distress Syndrome contains two main symptoms, each of which can be evaluated as 0, 2, 4 and 6 points. 6 sub-symptoms, each of which can be evaluated as 0, 1, 2, and 3 points. The scale has a minimum score of 0 and a maximum of 30 points, with the higher the score, the more severe the condition.

    Time frame: The end of Week 8

  8. TCM syndrome integral effective rate

    Recovery: Symptoms and signs disappear or basically disappear, and the score reduction rate of the syndrome ≥95%; Effective: Symptoms and signs improved, and the score reduction rate of the syndrome was ≥50%; Ineffective: no significant improvement in symptoms and signs, and the score reduction rate of the syndrome \<50%. Recovery: Symptoms and signs disappear or basically disappear, and the score reduction rate of the syndrome ≥95%; Effective: Symptoms and signs improved, and the score reduction rate of the syndrome was ≥50%; Ineffective: no significant improvement in symptoms and signs, and the score reduction rate of the syndrome \<50%. Recovery: Symptoms and signs disappear or basically disappear, and the score reduction rate of the syndrome ≥95%; Effective: Symptoms and signs improved, and the score reduction rate of the syndrome was ≥50%; Ineffective: no significant improvement in symptoms and signs, and the score reduction rate of the syndrome \<50%.

    Time frame: The end of Week 8

  9. the grade change of TCM single symptom from baseline

    The TCM Syndrome Scale for Postprandial Distress Syndrome contains two main symptoms, each of which can be evaluated as 0, 2, 4 and 6 points. 6 sub-symptoms, each of which can be evaluated as 0, 1, 2, and 3 points. The scale has a minimum score of 0 and a maximum of 30 points, with the higher the score, the more severe the condition.

    Time frame: The end of Week 8

  10. the proportion of subjects with sustained remission and no exacerbation of single symptoms at 12W compared with 8W

    There are 5 items in the Likert scale, with a minimum score of 1 and a maximum of 7 points for each item. The scale has a minimum score of 0 and a maximum of 35 points, with higher scores and more severe conditions. Among them, the subjects selected (1) and (2) are defined as having sustained remission from treatment; Subjects selected (3) and (4) were defined as having no exacerbation of disease; Subjects selected (5), (6), and (7) were defined as having exacerbated disease.

    Time frame: The end of Week 12

07

Study locations

2 of 18 sites recruiting
  • Guang'anmen Hospital, China Academy of Chinese Medical Sciences
    Beijing, Beijing Municipality, China
    Not yet recruiting
    • Yuning Bai · Contact13366266838
  • Gansu Provincial Hospital of Traditional Chinese Medicine
    Lanzhou, Gansu, China
    Not yet recruiting
    • Xudong Tian · Contact15002591589
  • The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
    Guiyang, Guizhou, China
    Not yet recruiting
    • Sufang Zhou · Contact13639082908
  • Hebei Provincial Hospital of Traditional Chinese Medicine
    Shijiazhuang, Hebei, China
    Not yet recruiting
    • Qian Yang · Contact13832355120
  • The Second Affiliated Hospital of Xingtai Medical College
    Xingtai, Hebei, China
    Not yet recruiting
    • Shuangzhao Xu · Contact15612978266
  • Baoding No. 1 Hospital of Traditional Chinese Medicine
    Baoding, Heibei, China
    Not yet recruiting
    • Jianhai Niu · Contact15731291866
  • The First People's Hospital of Luoyang City
    Luoyang, Henan, China
    Recruiting
    • Hongling Liu · Contact18538882095
  • The Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin, China
    Not yet recruiting
    • Yan Leng · Contact15948000725
  • General Hospital of the Northern Theater of the Chinese People's Liberation Army
    Shenyang, Liaoning, China
    Not yet recruiting
    • Yang Gong · Contact13309888136
  • The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
    Shenyang, Liaoning, China
    Not yet recruiting
    • Yufeng Li · Contact18102456191
  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Shengquan Fang · Contact18930566355
  • The Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
    Xianyang, Shanxi, China
    Not yet recruiting
    • Jiehong Wang · Contact15091063809
  • The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
    Chengdu, Sichuan, China
    Recruiting
    • Peimin Feng · Contact18981885791
  • West China Hospital Sichuan University
    Chengdu, Sichuan, China
    Not yet recruiting
    • Qing Xia · Contact18980601723
  • The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
    Tianjin, Tianjin Municipality, China
    Not yet recruiting
    • Zhenghua Zhou · Contact15202248272
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Not yet recruiting
    • Ying Zhang · Contact13708450827
  • Zhejiang Provincial Hospital of Traditional Chinese Medicine
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Bin Lv · Contact13906515409
  • Wenzhou Hospital of Traditional Chinese Medicine
    Wenzhou, Zhejiang, China
    Not yet recruiting
    • Yaoming Zeng · Contact13867704929
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 20, 2024
StartActual
Feb 27, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06696261
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Feb 27, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Peimin Feng, Doctor
Contact
76262251@qq.com
18981885791

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion